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Abstract
Background: Schizophrenia is a complex, multifactorial psychiatric disorder. Our previous findings indicated that
altered functional activity of the complement system, a major mediator of the immune response, is implicated in
the pathogenesis of schizophrenia. In order to explore whether these alterations are genetically determined or not,
in the present study we evaluated the possible association of complement C1Q component gene variants with
susceptibility to schizophrenia in Armenian population, focusing on four frequent single nucleotide polymorphisms
(SNPs) of C1QA and C1QB genes.
Methods: In the present study four SNPs of the complement C1Q component genes (C1QA: rs292001, C1QB
rs291982, rs631090, rs913243) were investigated in schizophrenia-affected and healthy subjects. Unrelated
Caucasian individuals of Armenian nationality, 225 schizophrenic patients and the same number of age- and sex-
matched healthy subjects, were genotyped. Genotyping was performed using polymerase chain reaction with
sequence-specific primers (PCR-SSP) and quantitative real-time (qRT) PCR methods.
Results: While there was no association between C1QA rs292001, C1QB rs913243 and rs631090 genetic variants
and schizophrenia, the C1QB rs291982*G minor allele was significantly overrepresented in schizophrenic patients (G
allele frequency 58%) when compared to healthy subjects (46%, OR = 1.64, pcorr = 0.0008). Importantly, the
susceptibility for schizophrenia was particularly associated with C1QB rs291982 GG genotype (OR = 2.5, pcorrected =
9.6E-5).
Conclusions: The results obtained suggest that C1QB gene may be considered as a relevant candidate gene for
susceptibility to schizophrenia, and its rs291982*G minor allele might represent a risk factor for schizophrenia at
least in Armenian population. Replication in other centers/populations is necessary to verify this conclusion.
Background
Schizophrenia is a complex and severe psychiatric disor-
der manifested by a disruption in cognition and emotion
along with negative (avolition, alogia, apathy, poor social
functioning) and positive (hallucinations, delusions)
symptoms [1,2]. According to the neurodevelopmental
theory, the etiology of schizophrenia may involve patho-
logical processes in the brain induced by environmental
factors during the early stage of brain formation
[reviewed in [3]]. These processes result in genetic
abnormalities leading to dysfunction of specific neural
network, which might contribute to the premorbid signs
for the later developed schizophrenia [3]. Evidence from
epidemiological and genetic studies suggest a high
degree of heritability of schizophrenia and point to a
number of potential candidate genes that may be per-
turbed early in development leading ultimately to the
development of psychotic symptoms [reviewed in [3-5]].
However, the molecular etiopathomechanisms of this
disorder are still unclear.
Our recent studies indicate the crucial role of the
immune system in schizophrenia and provide evidence
on the alterations in the major mediator of the immune
response, the complement system, in pathogenesis of
this disorder [6-13]. In particular, increased functional
activities of the complement classical pathway and C1Q
protein, the initiator of the complement classical
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cascade, in schizophrenia-affected subjects has been
found [8,10]. These findings are of special interest
accounting for a positive linkage of schizophrenia with
chromosome 1p36 loci located nearby C1QA and C1QB
genes (1p36.12) [14,15]. Notably, for other components
of the complement association of genetic polymorph-
isms with schizophrenia has been demonstrated [11,16].
In addition association of genetic diversity of HLA-III
encoding complement proteins with susceptibility to
schizophrenia has been also shown [17]. However, no
data regarding association of C1Q encoding genes
(C1QA and C1QB) polymorphisms to schizophrenia
have been published yet. To explore whether the altera-
tions in C1q activity in schizophrenia are genetically
determined or not, in the present study we evaluated
the possible association of complement C1Q component
gene variants with susceptibility to schizophrenia in
Armenian population, focusing on four C1QA and
C1QB intronic single nucleotide polymorphisms (SNPs);
two tagged SNPs were selected by Martens et al. [2009]
using HapMap project [18] and the other two were cho-
sen according to their frequent appearance in European
Caucasoid population (minor allele frequency > 10%)
and their potential functional effect (gain/loss of binding
site for transcription factors) [19-22]. To our knowledge,
this is the first study investigating association of the
C1QA and C1QB genetic variants with schizophrenia.
This study might contribute to understanding the mole-




In total, 450 unrelated Caucasian individuals of Arme-
nian nationality living in Armenia (225 schizophrenic
patients and 225 healthy subjects) were enrolled in this
study. All patients (female/male: 71/154, mean age ±
SD: 44.2 ± 9.8 years, age at the first-onset of illness:
26.4 ± 8.3 years, duration of illness: 19.5 ± 7.2 years,
patients with/without family history of psychiatric disor-
ders: 94/131) were diagnosed as paranoid schizophrenics
(ICD-10 code: F20.0, DSM-IV-TR code: 295.30) by two
independent experienced psychiatrists [1,2]. The affected
subjects were recruited from the clinics of the Psychia-
tric Medical Center of the Ministry of Health of the
Republic of Armenia (MH RA). Age- and sex-matched
healthy volunteers (female/male: 71/154, mean age ±
SD: 42.6 ± 9.2 years) were recruited among the staff and
blood donors of the Erebouni Medical Center MH RA.
Exclusion criteria for healthy subjects included psychia-
tric illness during lifetime, any serious neurological or
endocrine disorder, any medical condition or treatment
known to affect the brain, or meeting DSM-IV criteria
for mental retardation as determined from the non-
patient version of the Structured Clinical Interview for
DSM-IV-TR Axis I Disorders [23]. Exclusion criteria for
all study participants included any serious medical disor-
der. All subjects gave their informed consents to partici-
pate in the study, which was approved by the Ethical
Committee of the Institute of Molecular Biology of the
National Academy of Sciences RA.
Genomic DNA extraction
Genomic DNA samples were isolated from fresh blood
according to the standard phenol-chloroform method
[24] and stored at -30°C until further use.
Genotyping analysis
All DNA samples were genotyped for four SNPs, namely
C1QA rs292001, C1QB rs913243, rs291982 and
rs631090. C1QA rs292001, C1QB rs291982 and
rs631090 SNPs were genotyped by polymerase chain
reaction with sequence-specific primers (PCR-SSP)
under the conditions described elsewhere [25]. All pri-
mers for PCR-SSP were designed using the genomic
sequences in the GenBank (http://www.ncbi.nlm.nih.gov,
GenBank ID:712, 713). The primer sequences for three
mentioned SNPs were as follows: 1) rs292001: allele G,
reverse 5’GAT GCC CGG ATG CAA ATT AC, allele A,
reverse 5’GAT GCC CGG ATG CAA ATT AT, con-
stant forward 5’AGG CTT CAG AGA CTC ACA TTC;
2) rs291982: allele T, reverse 5’ACC TTT GCC CAG
ATC CAA ATT, allele G, reverse 5’ACC TTT GCC
CAG ATC CAA ATG, constant forward 5’AGC CAC
AAG TCC CAA TGA GA; 3) rs631090: allele T, for-
ward 5’CAC GGA TCT CTT ACC ATT AAA T, allele
C, forward 5’CAC GGA TCT CTT ACC ATT AAA C,
constant reverse 5’CAT CTG TGA AAT GGG GAT
GAA. The presence/absence of allele-specific amplicons
was visualized by 2% agarose gel stained with ethidium
bromide fluorescence in reference to a molecular weight
marker. Genotypes for C1QB rs913243G/T SNP were
determined using TaqMan SNP genotyping assay
(Applied Biosystems, Assay ID C_3176751_10) accord-
ing to the manufacturer’s instruction. Randomly selected
samples (n = 45; 10% of the total number) were ampli-
fied twice to check for confidence of genotyping, and in
each case complete concordance was obtained.
Statistical analysis
The distributions of genotypes for all investigated SNPs
were checked for correspondence to the Hardy-Wein-
berg (H-W) equilibrium. In order to find potential rele-
vance of the selected SNPs to schizophrenia, their allele
and genotype frequencies (carriage rates) in patients and
control subjects were compared. The calculations of
allele and genotype frequencies were based on the
observed number of genotypes. Estimated proportion of
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haplotypes and linkage disequilibrium (LD) between
investigated loci were calculated using SNP analyzer
software [26]. Maximum-likehood (ML) haplotype fre-
quencies in patients and control subjects were estimated
using an expectation-maximization (EM) algorithm [27].
The significance of differences between allele and geno-
type frequencies in both groups was determined using
Pearson’s Chi-square test. The odds ratio (OR), 95%
confidence interval (CI), and Pearson’s p-value were cal-
culated. Statistical power of the present study was calcu-
lated according to the protocol described elsewhere [28].
P-values were adjusted by Bonferroni multiple correc-
tion approach [29], and those less than 0.05 were con-
sidered statistically significant.
Results
The genotype distributions of studied SNPs in both
patients and controls complied with H-W equilibrium
(p > 0.05). Statistical power of the present study, indicat-
ing the difference in the C1QB rs291982*G allele fre-
quency between the patients and healthy controls for
the odds ratio (OR) 2.5 reached 100%, for OR = 2.0
99.9%, while for OR = 1.2 was 38.8%.
The frequencies of all studied genetic variants in the
groups of schizophrenic patients and control subjects
are shown in Table 1. C1QA rs292001 and C1QB
rs913243 polymorphisms were almost equally repre-
sented in both groups (p > 0.05). By contrast, significant
differences in the C1QB rs631090*C (22% vs 17%, OR =
1.4, 95%CI: 1.01-1.95, pnominal = 0.044) and rs291982*G
(58% vs 46%, OR = 1.64, 95%CI: 1.26-2.13, pnominal =
0.0002) minor allele frequencies between schizophrenic
patients and healthy subjects were found. After Bonfer-
roni correction for the number of tested loci (n = 4),
C1QB rs291982*G minor allele remained more frequent
at significant level in schizophrenics compared to con-
trols (pcorrected = 0.0008). The overall distribution of
C1QB rs291982 genotypes differed between the patients
and controls (pcorrected = 0.0004, 2 degrees of freedom,
d.f.) due to the overrepresentation of rs291982 GG
homozygotes among schizophrenics (36% vs 19%, pnom-
inal = 2.4E-5, pcorrected = 9.6E-5, 1 d.f., OR = 2.5, 95%Cl:
1.62-3.85). Further, the rs291982 GG genotype was asso-
ciated with increased risk for schizophrenia when com-
pared to both TG (pcorrected = 0.0004) and TT (pcorrected
= 0.0016) genotypes. In contrast, the susceptibility to
schizophrenia was almost equal in rs291982 TG and TT
genotypes (pnominal = 0.82). These results suggest that
the C1QB rs291982*G minor allele might be considered
as a risk factor for schizophrenia in a homozygous status
(GG genotype, recessive model), at least in Armenian
population.
Haplotype analysis was performed to confirm the
observed association and to estimate the ML C1QA/
C1QB (rs292001/rs913243/rs291982/rs631090) haplo-
type frequencies. In total, 16 haplotypes in each group
Table 1 Distribution of C1QA/C1QB genotypes and carriage of minor alleles in patients with schizophrenia (SCZ) and
healthy subjects (Controls).
SNP ID Genotype 1 Genotype 2 Genotype 3 Allele 1 Allele 2 Carriage
rs292001 GG GA AA G A A
SCZ 76 (0.34) 112 (0.50) 37 (0.16) 264 (0.59) 186 (0.41) 149 (0.66)
Controls 59 (0.26) 119 (0.53) 47 (0.21) 237 (0.53) 213 (0.47) 166 (0.74)
p 0.170a 0.070b 0.080c
rs913243 GG GT TT G T T
SCZ 68 (0.30) 123 (0.55) 34 (0.15) 259 (0.58) 191 (0.42) 157 (0.70)
Controls 64 (0.28) 124 (0.56) 37 (0.16) 254 (0.56) 196 (0.44) 161 (0.72)
p 0.882a 0.638b 0.679c
rs291982 TT TG GG T G G
SCZ 46 (0.20) 97 (0.44) 82 (0.36) 189 (0.42) 261 (0.58) 179 (0.80)
Controls 61 (0.27) 122 (0.54) 42 (0.19) 244 (0.54) 206 (0.46) 164 (0.73)
p 0.0001a 0.0002b 0.097c
rs631090 TT TC CC T C C
SCZ 135 (0.60) 79 (0.35) 11 (0.05) 349 (0.78) 101 (0.22) 90 (0.40)
Controls 153 (0.68) 67 (0.30) 5 (0.02) 373 (0.83) 77 (0.17) 72 (0.32)
p 0.113a 0.044b 0.077c
The data are presented as absolute numbers with proportions (%) in parentheses.
a nominal p-values for comparison of overall distribution of C1QA/C1QB genotypes between SCZ and Controls (2 degrees of freedom);
b nominal p-values for comparison of Allele 2 proportion between SCZ and Controls;
c nominal p-values for comparison of Allele 2 carriage between SCZ and Controls.
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of study subjects were estimated. Interestingly, haplotype
comparison between patients and healthy controls
revealed five haplotypes with nominally significant dif-
ferences between schizophrenic patients and controls,
namely, A-T-T-T (haplotype frequencies in patients vs
controls: 13% vs 19%, OR = 0.57, 95%CI: 0.40-0.81,
pnominal = 0.02, pcorrected = 0.32), A-G-T-T (4% vs 11%,
OR = 0.41, 95%CI: 0.23-0.74, pnominal = 0.002, pcorrected =
0.03), A-G-G-T (8% vs 4%, OR = 2.02, 95%CI: 1.13-3.63,
pnominal = 0.015, pcorrected = 0.24), G-G-G-C (8% versus
2%, OR = 1.99, 95%CI: 1.03-3.84, pnominal = 0.049, pcor-
rected = 0.78), and A-T-G-C (1% vs 0.6%, OR = 4.43, 95%
CI: 1.25-15.66, pnominal = 0.009, pcorrected = 0.14), only
one of which (A-G-T-T) remained significant after the
correction for the number of haplotypes. The difference
in A-G-T-T haplotype between patients and controls
suggested that the C1QB rs291982 major T allele is less
frequent in patients with schizophrenia than in controls.
Importantly, these data are in complete concordance
with major allele frequencies in both groups. The haplo-
type analysis, therefore, confirmed detected association
of the C1QB rs291982 variant with schizophrenia.
In both patients and controls pair-wise linkage dise-
quilibrium (LD) between the investigated C1QB
rs913243, rs291982, and rs631090 SNPs was determined.
LD blocks of C1QB gene SNPs and values of absolute D’
as well as r2 for both groups are presented in Figure 1.
Discussion
In this study the possible association of several poly-
morphisms of the complement C1Q component gene
with susceptibility to schizophrenia was evaluated. No
association of C1QA rs292001, C1QB rs913243 and
rs631090 variants with disease was observed, whereas
positive association of C1QB rs291982*G variant and
namely GG genotype with schizophrenia was found.
The results suggest that the C1QB rs291982*G minor
allele might be in a homozygous status a risk factor for
schizophrenia at least in Armenian population. There-
fore, C1QB gene may be considered as a relevant candi-
date gene for susceptibility to schizophrenia.
The functionality of C1QA rs292001 and C1QB
rs631090 has been previously shown in lupus erythema-
tosus [18]. Nevertheless, our study revealed no associa-
tion of these two functional variants with schizophrenia.
At present, there are no published data on functionality
of the C1QB rs291982 and rs913243 polymorphisms. In
order to explore possible functional role of these genetic
variants, we use the web server ALGGEN, a convenient
tool for identification of the functional effects of SNPs
[30]. Analysis showed that both C1QB rs291982 and
rs913243 SNPs were found to be intronic enhancers.
Thus, the C1QB rs291982 minor G allele contains bind-
ing sites for transcription factors forkhead box P3
(FOXP3, also known as hepocyte nuclear factor 3
(HNF3), forkhead homologue 2 or HFH-2), progesterone
receptor isoform A (PRA) and B (PRB), absent in the T
major allele. Further, the rs913243 G/T polymorphism
of the C1QB gene leads to loss of binding sites of gluco-
corticoid receptor-alpha and retinoid × receptor-alpha
transcription factors. Whereas these types of functional
effects have low phenotypic risk [31], the results of our
analysis might indicate the functionality of the C1QB
rs291982 and rs913243 SNPs as enhancers, transcrip-
tion-stimulating DNA regulatory elements [32]. Impor-
tantly, these transcription factors might have an indirect
impact on the immune system [19-22], therefore, might
contribute to the etiology of schizophrenia taken into
account immune system alterations in this disease
[6-13].
The association between the C1QB rs291982*G
genetic variant and schizophrenia obtained in our study
may suggest the etiological significance of C1QB gene in
schizophrenia in Armenian population. Furthermore,
this finding may reflect implication of neurodegenerative
component in schizophrenia [3]. Thus, Grewal et al
(1999) demonstrated overexpression of C1QB in the
areas undergoing neurodegeneration [33]. In addition,
recent studies showing alterations in expression of
C1QB gene in hippocampus and cerebral cortex in the
animal models of Alzheimer’s disease [33,34], having
some clinical features shared with schizophrenia such as
neuron loss and cognitive impairment [1].
There may be another possible explanation of the
association observed in our study in the light of the vas-
cular-inflammatory theory of schizophrenia [35]. This
Figure 1 LD blocks of C1QB gene rs913243/rs291982/rs631090
SNPs and values of absolute D’ as well as r2 for patients with
schizophrenia (SCZ) and healthy subjects (Controls).
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theory is based on observations that inflammatory vas-
cular disease of the brain leads to psychosis and exhibits
a fluctuating course as seen in schizophrenia, and that
disturbances of central nervous system blood flow have
repeatedly been observed in people with schizophrenia
[35]. Interestingly, it has been demonstrated that the
human cerebrovascular smooth muscle cells (HCSMC)
isolated from cortical vessels derived from postmortem
brains can express mRNAs for complement C1QB gene.
As HCSMC are closely associated with amyloid beta
deposits in vessels in the brain, their production of com-
plement proteins could amplify the proinflammatory
effects of amyloid in the perivascular environment,
further compromising brain vascular integrity [36].
Also, the observed differences in the C1QB gene LD
blocks between the patients with schizophrenia and con-
trol subjects may suggest that C1QB rs291982*G allele is
a marker of a haplotype carrying “causative” variant
located nearby on the first chromosome. In this context
it is quite important to note that chromosomal region
1p36 carrying C1QB gene has already been associated
with schizophrenia in two genome-wide linkage scans
[14,15].
Conclusions
The results obtained suggest that C1QB gene may be
considered as a relevant candidate gene for susceptibility
to schizophrenia, and its rs291982*G minor allele might
represent a risk factor for schizophrenia at least in
Armenian population.
Limitations of our study
The first limitation of our study is related to the rela-
tively small sample size of both study groups (225
patients with schizophrenia and 225 healthy subjects),
which, however, accounting for total population of
Armenia (about 2,800,000) and the incidence of schizo-
phrenia (1%) is nearly optimal for this population. In
addition, the statistical power of this study, indicating
the difference in the C1QB rs291982*G allele frequency
between the patients and healthy controls for the OR =
2.5 reached 100%, for OR = 2.0 99.9%, while for OR =
1.2 was 38.8%. Secondly, we did not reveal how the
C1QB rs291982 SNP, significantly associated with schi-
zophrenia in our study, alters the C1QB function. Repli-
cation of these data in other centres/populations is
required to confirm our results, and also, in the future
investigations of functional effects of this genetic variant
would be desirable.
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